Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 6, 2005, Pages 1074-1080

  Brook, I ^a   Germana, A ^a   Giraldo, D E ^a   Camp Hyde, T D ^a   Bolduc, D L ^a   Foriska, M A ^a   Elliott, T B ^a   Thakar, J H ^a   Shoemaker, M O ^a   Jackson, W E ^a   Ledney, G D ^a  

^a ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

Author keywords

Anthrax; Ciprofloxacin; Clindamycin; Irradiation; Moxifloxacin; Translocation

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLINDAMYCIN; COBALT 60; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BLOOD; COBALT THERAPY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GAMMA IRRADIATION; LETHALITY; LIVER; LUNG; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; PROVOCATION TEST; RADIATION DOSE; RECORDING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TRACHEA;

ADMINISTRATION, ORAL; ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACILLUS ANTHRACIS; BLOOD; CIPROFLOXACIN; CLINDAMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; GAMMA RAYS; INJECTIONS, SUBCUTANEOUS; LIVER; LUNG; MICE; QUINOLINES; RADIATION INJURIES, EXPERIMENTAL; SURVIVAL ANALYSIS;

EID: 29444450899     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki367     Document Type: Article

References (39)

1. Dewan PK, Fry AM, Laserson K et al. Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis 2002; 8: 1066.
2. Christopher GW, Cieslak TJ, Pavlin JA et al. Biological warfare. A historical perspective. JAMA 1997; 278: 412-17.
3. Franz DR, Jahrling PB, Friedlander AM et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411.
4. Inglesby TV, Henderson DA, Bartlett JG et al. Anthrax as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281: 1735-45.
5. Pile JC, Malone JD, Eitzen EM et al. Anthrax as a potential biological warfare agent. Arch Intern Med 1998; 158: 429-34.
6. World Health Organization. Health Aspects of Chemical and Biological Weapons: A Report of a WHO Group of Consultants. Geneva: World Health Organization, 1970.
7. Alper T. Cellular Radiobiology. New York: Cambridge University Press, 1979.
8. Brook I, Elliott TB, Harding RA et al. Susceptibility of irradiated mice to Bacillus anthracis Sterne by the intratracheal route of infection. J Med Microbiol 2001; 50: 702-11.
9. Falgas ME, Gorbach SL. Clindamycin and metronidazole. Med Clin North Am 1995; 79: 845-52.
10. Athamna A, Massalha M, Athamna M et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother 2004; 53: 247-51.
11. Mohammed MJ, Marston CK, Popovic T et al. Antimicrobial susceptibility testing of Bacillus anthracis: Comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol 2002; 40: 1902-7.
12. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995; 20: S154-7.
13. Gemmell CG, Peterson PK, Schmeling D et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981; 67: 1249-56.
14. Gemmell CG, Lambe DW, Santos JI. The influence of clindamycin on the host-parasite relationship. In: Clindamycin in the Treatment of Human Infections. Michigan: Pharmacia & Upjohn Company, 1997; 3-10-3-12.
15. Zhao X, Wang JY, Xu C. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother 1998; 42: 956-8.
16. Friedlander AM, Welkos SL, Pitt ML et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167: 1239-43.
17. Brook I, Elliott TB, Pryor HI et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 2001; 18: 559-62.
18. Price LB, Vogler A, Pearson T et al. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother 2003; 47: 2362-5.
19. Casin I. Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in Salmonella enterica Typhimurium isolates in humans. Emerg Infect Dis 2003; 9: 1455-7.
20. Esposito S, Gupta A, Thadepalli H. In vitro synergy of ciprofloxacin and three other antibiotics against Bacteroides fragilis. Drugs Exp Clin Res 1987; 13: 489-92.
21. Neu HC. Synergy and antagonism of combinations with quinolones Eur J Clin Microbiol Infect Dis 1991; 10: 255-61.
22. Centers for Disease Control and Prevention. Additional options for preventive treatment for persons exposed to inhalational anthrax. Morb Mortal Wkly Rep 2001; 50: 1142-51.
23. Athamna A, Athamna M, Nura A et al. Is in vitro antibiotic combination more effective than single-drug therapy against anthrax? Antimicrob Agents Chemother 2005; 49: 1323-5.
24. National Research Council. Guide for the care and use of laboratory animals. In: Institute of Laboratory Animal Resources Commission on Life Sciences. Washington, DC: National Academy Press, 1996.
25. Schaeffer P, Millet J, Aubert JP. Catabolic repression of bacterial sporulation. Proc Natl Acad Sci USA 1965; 54: 704-11.
26. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition: Approved Standard M7-A3. NCCLS, Villanova, PA, 1993.
27. Saffiotti W, Cefis F, Kolb LH. A method for the experimental induction of bronchogenic carcinoma. Cancer Res 1968; 28: 104-24.
28. Yehezkelli Y, Dushnitsky T, Hourvitz A. Radiation terrorism - the medical challenge. Isr Med Assoc J 2002; 4: 530-4.
29. Onyeji CO, Khanh QB, Owens RC et al. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antimicrob Agents 1999; 12: 107-14.
30. Koh AY, Priebe GP, Pier GB. Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun 2005; 73: 2262-72.
31. Ernst EJ, Klepser ME, Petzold CR et al. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcallung infection. Pharmacotherapy 2002; 22: 463-70.
32. Brook I, MacVittie TJ, Walker RI. Effect of radiation dose on the recovery of aerobic and anaerobic bacteria from mice. Can J Microbiol 1986; 32: 719-22.
33. Hirata N, Hiramatsu K, Kishi K et al. Pretreatment of mice with clindamycin improves survival of endotoxic shook by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother 2001; 45: 2638-42.
34. 60Co-γ-irradiated mice. Antimicrob Agents Chemother 2002; 46: 3463-71.
35. Brook I, Elliott TB. Quinolone therapy in the prevention of mortality after irradiation. Radiat Res 1991; 128: 100-3.
36. Knudson GB. Treatment of anthrax in man: History and current concepts. Mil Med 1986; 151: 71-7.
37. Boeckh M, Lode H, Deppermann KM et al. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother 1990; 34: 2407-14.
38. Jernigan JA, Stephens DS, Ashford DA et al. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg Infect Dis 2001; 7: 933-44.
39. Blondeau JM, Laskowski R, Bjarnason J et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000; 14: 45-50.